<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942022000100032</article-id>
<article-id pub-id-type="doi">10.30827/ars.v63i1.22264</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Actividad relajante del músculo esquelético de diferentes formulaciones de niosomas span 60]]></article-title>
<article-title xml:lang="es"><![CDATA[Skeletal muscle relaxant activity of different formulation of span 60 niosomes]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Keservani]]></surname>
<given-names><![CDATA[Raj Kumar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gautam]]></surname>
<given-names><![CDATA[Surya Prakash]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,IKG Punjab Technical University  ]]></institution>
<addr-line><![CDATA[Jalandhar Punjab]]></addr-line>
<country>India</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,CT Institute of Pharmaceutical Sciences  ]]></institution>
<addr-line><![CDATA[Jalandhar Punjab]]></addr-line>
<country>India</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<volume>63</volume>
<numero>1</numero>
<fpage>32</fpage>
<lpage>44</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942022000100032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942022000100032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942022000100032&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Spasticity is a disease of motor neurons that manifests as accelerated muscle tone and stiffness. The niosomes can be formulated with the aid of proper adjustment of process parameters to enhance baclofen entrapment and sustaining the drug release.  Method:  The main purpose of this study is to compare different formulations of span 60 niosomes containing baclofen for skeletal muscle relaxant activity on mice (Swiss albino mice) by rota rod method.  Results:  The particle size of formulated niosomes was in the range of 3.62±0.54-4.08±0.64 µm and these were smooth, circular fit and generally small multilamellar. Entrapment efficiency of optimized formulation was 88.44±0.28 %. The most extreme % cumulative drug release was 87.88±8.66% after 10 h. The formulation stored at 4±2 °C temperature shows better stability (96.65±0.45) contrasted with raised temperature. Swiss albino mice were utilized for in vivo study and displayed improved muscle relaxant action as far as no. of tumbles from rota rod apparatus (p value =0.001) are concerned.  Conclusions:  Nonetheless, diazepam treated mice were observed to have higher muscle relaxation than any dose of formulation tested. The formulation F9 shows better skeletal muscle relaxant activity as compared to F6, F7, F8 and F10 on mice (Swiss albino mice) by the rota rod technique.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La espasticidad es una enfermedad de las neuronas motoras que se manifiesta como aceleración del tono muscular y rigidez. Los niosomas se pueden formular con la ayuda de un ajuste adecuado de los parámetros del proceso para mejorar el atrapamiento del baclofeno y mantener la liberación del fármaco.  Método:  El objetivo principal de este estudio es comparar diferentes formulaciones de niosomas span 60 que contienen baclofeno para la actividad relajante del músculo esquelético en ratones (ratones albinos suizos) mediante el método de rota rod.  Resultados: El tamaño de partícula de los niosomas formulados estaba en el rango de 3,62 ± 0,54-4,08 ± 0,64 µm y eran suaves, de ajuste circular y generalmente multilaminares pequeños. La eficiencia de atrapamiento de la formulación optimizada fue 88,44 ± 0,28%. El porcentaje de liberación acumulada de fármaco más extremo fue 87,88 ± 8,66% después de 10 h. La formulación almacenada a una temperatura de 4 ± 2 ° C muestra una mejor estabilidad (96,65 ± 0,45) en comparación con la temperatura elevada. Se utilizaron ratones albinos suizos para el estudio in vivo y mostraron una acción relajante muscular mejorada hasta donde no. de caídas desde el aparato de varilla de rotación (valor de p = 0,001).  Conclusiones:  No obstante, se observó que los ratones tratados con diazepam tenían una mayor relajación muscular que cualquier dosis de formulación probada. La formulación F9 muestra una mejor actividad relajante del músculo esquelético en comparación con F6, F7, F8 y F10 en ratones (ratones albinos suizos) mediante la técnica de rota rod.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Niosomas]]></kwd>
<kwd lng="es"><![CDATA[baclofeno]]></kwd>
<kwd lng="es"><![CDATA[diazepam]]></kwd>
<kwd lng="es"><![CDATA[ratones albinos suizos]]></kwd>
<kwd lng="es"><![CDATA[relajante del músculo esquelético]]></kwd>
<kwd lng="en"><![CDATA[Niosomes]]></kwd>
<kwd lng="en"><![CDATA[baclofen]]></kwd>
<kwd lng="en"><![CDATA[diazepam]]></kwd>
<kwd lng="en"><![CDATA[Swiss albino mice]]></kwd>
<kwd lng="en"><![CDATA[skeletal muscle relaxant]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazi]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Mandal]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Biswas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Guha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Behera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuotsu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niosome: A future of targeted drug delivery systems]]></article-title>
<source><![CDATA[J Adv Pharm Technol Res]]></source>
<year>2010</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>374-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jadon]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Gajbhiye]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jadon]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Gajbhiye]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Ganesh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced oral bioavailability of griseofulvin via niosomes]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>1186-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ge]]></surname>
<given-names><![CDATA[Xuemei]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2019</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>55</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheena]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[UV]]></given-names>
</name>
<name>
<surname><![CDATA[Kamath]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Uma]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Udupa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niosomalwithaferin A, with better tumor efficiency]]></article-title>
<source><![CDATA[Indian J Pharm Sci]]></source>
<year>1998</year>
<volume>60</volume>
<page-range>45-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of liposomes and niosomes on skin permeation of enoxacin]]></article-title>
<source><![CDATA[Int J of Pharm]]></source>
<year>2001</year>
<volume>219</volume>
<page-range>61-72</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Udupa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chandraprakash]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Umadevi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pillai]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation and evaluation of methotrexate niosomes]]></article-title>
<source><![CDATA[Drug Dev Ind Pharm]]></source>
<year>1993</year>
<volume>19</volume>
<page-range>1331-42</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parthasarathi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Udupa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Umadevi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pillai]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niosome-encapsulated vincristine sulfate: improved anticancer activity with reduced toxicity in mice]]></article-title>
<source><![CDATA[J. Drug Targ]]></source>
<year>1994</year>
<volume>2</volume>
<page-range>173-82</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uchegbu]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[Double]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Turton]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Florence]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse]]></article-title>
<source><![CDATA[Pharma Res]]></source>
<year>1995</year>
<volume>12</volume>
<page-range>1019-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Baillie]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five nonionic surfactant vesicle preparations of sodium stibogluconate]]></article-title>
<source><![CDATA[J Drug Targ]]></source>
<year>1995</year>
<volume>3</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blazek-Welsh]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maltodextrin-based proniosomes]]></article-title>
<source><![CDATA[AAPS pharm Sci]]></source>
<year>2001</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arunothayanun]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Turton]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Uchegbu]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[Florence]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation and in vitro in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical tubular niosomes]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>1999</year>
<volume>88</volume>
<page-range>34-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uchegbu]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[Double]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Turton]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Florence]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>1995</year>
<volume>12</volume>
<page-range>1019</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshioka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sternberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Florence]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation and Properties of Vesicles (Niosomes) Of Sorbitan Monoesters (Span-20, Span-40, Span-60 and Span-80) and A Sorbitan Triester (Span-85)]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>1994</year>
<volume>105</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[YB]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro skin permeation of estradiol from various proniosome formulations]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2001</year>
<volume>215</volume>
<page-range>91-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manconi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sinico]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valenti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Loy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fadda]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niosomes as carriers for tretinoin. I. preparation and properties]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2002</year>
<volume>234</volume>
<page-range>237-48</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manconi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valenti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sinico]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Loy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fadda]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niosomes as carriers for tretinoin II. Influence of vesicular incorporation on tretinoin photostability]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2003</year>
<volume>260</volume>
<page-range>261-72</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haselkorn]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Little]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spasticity Management in Multiple Sclerosis: Evidence-Based Management Strategies for Spasticity Treatment in Multiple Sclerosis]]></article-title>
<source><![CDATA[J Spinal Cord Med]]></source>
<year>2005</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>167-99</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burchiel]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pain and spasticity after spinal cord injury: mechanisms and treatment]]></article-title>
<source><![CDATA[Spine]]></source>
<year>2001</year>
<volume>26</volume>
<numero>24Suppl</numero>
<issue>24Suppl</issue>
<page-range>S146-60</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brogden]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Speight]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1974</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davidoff]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antispasticity drugs: mechanisms of action]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1985</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>107-16</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagstaff]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bryson]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1997</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>435-52</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nance]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tizanidine: An a2-agonist imidazoline with antispasticity effects]]></article-title>
<source><![CDATA[Today's Ther Trends]]></source>
<year>1997</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-25</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goodkin]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs used to treat spasticity]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2000</year>
<volume>59</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>487-95</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Nathan]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[On the site of action of diazepam in spasticity in man]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>1967</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davidoff]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacology of spasticity]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1978</year>
<volume>28</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>46-51</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arunothayanun]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Turton]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Uchegbu]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[Florence]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation and in vitro and in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical tubular niosomes]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>1999</year>
<volume>88</volume>
<page-range>34-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baillie]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coombs]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Dolan]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-ionic surfactant vesicles (Niosomes) as delivery system for the anti- leishmanial drug, sodium stribogluconate]]></article-title>
<source><![CDATA[J Pharm Pharmacol]]></source>
<year>1986</year>
<volume>38</volume>
<page-range>502-5</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varsheny]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Tanwar]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Designing and characterization of verapamil hydrochloride niosomes]]></article-title>
<collab>lowalekar R.Rathore KS</collab>
<source><![CDATA[Indian Pharmacy]]></source>
<year>2007</year>
<volume>6</volume>
<page-range>77-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aggarwal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system]]></article-title>
<source><![CDATA[Int J Pharmac]]></source>
<year>2005</year>
<volume>290</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karki]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mamatha]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Subramanya]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Udupa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation, characterization and tissue diposition of niosomes containing isoniazide]]></article-title>
<source><![CDATA[Riv Jew Cent]]></source>
<year>2008</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>224-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doijad]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Manvi]]></surname>
<given-names><![CDATA[FV]]></given-names>
</name>
<name>
<surname><![CDATA[Swathi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rony]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niosomal drug delivery of cisplatin: development and characterization]]></article-title>
<source><![CDATA[Indian Drugs]]></source>
<year>2008</year>
<volume>45</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>713-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Discovery and Evaluation, Pharmacological Assays]]></source>
<year>2002</year>
<edition>2</edition>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer-Verlag Berlin Heidelberg]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keservani]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Suman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel vesicular approach for topical delivery of baclofen via niosomes]]></article-title>
<source><![CDATA[Lat Am J Pharm]]></source>
<year>2010</year>
<volume>29</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1364-70</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamboj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement]]></article-title>
<source><![CDATA[The Scientific World Journal]]></source>
<year>2014</year>
<volume>2014</volume>
<page-range>959741</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdelkader]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kamal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alany]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: Physicochemical characterization]]></article-title>
<source><![CDATA[Pharmazie]]></source>
<year>2010</year>
<volume>65</volume>
<page-range>811-7</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[Mitra]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Aggarwal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a vesicular system for effective ocular delivery of acetazolamide: a comprehensive approach and successful venture]]></article-title>
<source><![CDATA[J Drug Deliv Sci Technol]]></source>
<year>2007</year>
<volume>17</volume>
<page-range>33-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
